Visit the Liberty Health Sciences Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Liberty Health Sciences to Bring Solei Cannabis Brand to Florida and Massachusetts
Liberty signs amended licensing agreement with Aphria to include Solei in its growing portfolio of products
TORONTO, May 11, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company”) today announced it has signed an amended licensing agreement with Aphria Inc. (“Aphria”) to add Solei Sungrown Cannabis (“Solei”), to the Company’s growing portfolio of brands. Under the terms of the agreement, Liberty will be able to produce and sell Solei in Florida and Massachusetts, subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use, and from the Commonwealth of Massachusetts, Medical Use of Marijuana Program or the Massachusetts Cannabis Control Commission, if any.
We are incredibly excited to introduce Solei to the U.S. and to make this brand available to our patients throughout Florida, and soon Massachusetts. Solei is the perfect complement to Liberty’s patient-centric approach to medical cannabis. Solei hopes to make medical cannabis understandable to all of our patients in need in an easy-to-understand format.
George Scorsis, Director and CEO of Liberty
Solei will be available in a wide variety of product consumption alternatives, with easy-to-use instructions designed to simplify cannabis use.
Aphria is delighted to extend our strategic relationship with Liberty, as they continue to demonstrate leadership in Florida and soon other legal markets in the U.S. Medical cannabis patients in Florida and elsewhere will benefit from Solei’s uncomplicated and simplified approach to consuming cannabis, which really sets the brand apart in the marketplace.
Vic Neufeld, CEO of Aphria
Liberty’s Cannabis Education Centers will offer Solei alongside the Company’s currently lineup of brands to be offered to patients in Florida, including Aphria, Mary’s Medicinals, incredibles, incredible Extracts, and incredible Wellness. Solei products are expected to be available for sale by the end of July 2018.
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while the company focuses on significant near- and mid-term business opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. The company leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
For more information, please visit libertyhealthsciences.com
The most reliable, fact-based information on Liberty Health Sciences found only on its Investor Dashboard.
Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.